中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.02 seconds)

    Methods for treatment of conditions associated with lactosylceramide
    1.
    发明授权
    Methods for treatment of conditions associated with lactosylceramide 有权
    用于治疗与乳糖神经酰胺相关的病症的方法

    公开(公告)号：US06228889B1

    公开(公告)日：2001-05-08

    申请号：US09340341

    申请日：1999-06-25

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: A61K3116

    CPC classification number: A61K31/40 ,  A61K31/16 ,  A61K31/445 ,  A61K31/535

    Abstract: The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration for a mammal, particularly a human, of a therapeutically effective amount of a compound that inhibits UDPGal:GlcCer&bgr;1−>4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.

    Abstract translation: 本发明包括治疗和预防与乳糖神经酰胺相关的疾病，手术后疾病和细菌感染的方法。 所述方法通常提供给予哺乳动物特别是人类治疗有效量的抑制UDPGal：GlcCerβ1→4半乳糖神经酰胺（GalT-2）的化合物。 还提供了用于检测具有调节GalT-2的治疗能力的化合物的体外和体内测定。

    PECAM-1 GENOTYPE
    3.
    发明申请
    PECAM-1 GENOTYPE 审中-公开
    PECAM-1基因组

    公开(公告)号：US20090208934A1

    公开(公告)日：2009-08-20

    申请号：US11794871

    申请日：2006-01-05

    Applicant: Subroto Chatterjee ,  Heiming Wei

    Inventor： Subroto Chatterjee ,  Heiming Wei

    IPC: C12Q1/68 ,  C40B40/08 ,  C12N5/08

    CPC classification number: C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

    Abstract: The invention relates to methods of identifying inter-patient differences in genotype of PECAM-1 to diagnose and assess risk of arterial disease. It further relates to methods of identifying therapeutics agents for to treat coronary arterial disease, and to methods for determining and exploiting such differences to improve medical outcomes.

    Abstract translation: 本发明涉及鉴定PECAM-1基因型患者间差异以诊断和评估动脉疾病风险的方法。 它还涉及鉴定用于治疗冠状动脉疾病的治疗剂的方法，以及用于确定和利用这些差异以改善医学结果的方法。

    Receptor-based assays for pathogens
    4.
    发明授权
    Receptor-based assays for pathogens 失效
    基于受体的病原体测定

    公开(公告)号：US06528272B2

    公开(公告)日：2003-03-04

    申请号：US09019435

    申请日：1998-02-05

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: G01N3353

    CPC classification number: G01N33/545 ,  G01N33/54306 ,  G01N33/569 ,  G01N33/56911 ,  G01N33/56916 ,  G01N33/56938 ,  G01N33/56972 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57426 ,  G01N33/92 ,  G01N2405/10 ,  Y02A50/52 ,  Y10S435/975 ,  Y10S436/808

    Abstract: A rapid, simple, and inexpensive sandwich enzyme-linked receptor based immunodot assay detects pathogens or pathogenic products in test samples using receptors for a characteristic component of the pathogen. This assay is widely applicable because it is highly specific, it does not require special equipment, and the results can be obtained within a few hours with the naked eye. Since the lipid-based receptors have a long-shelf life, they can be easily stored and used for a long time.

    Abstract translation: 基于快速，简单且廉价的夹心酶联免疫斑点免疫测定法利用受体作为病原体的特征成分检测试验样品中的病原体或致病物。 该测定法广泛适用，因为它是高度特异性的，不需要特殊设备，并且可以在肉眼几小时内获得结果。 由于基于脂质的受体具有长寿命，因此它们可以容易地长时间储存​​和使用。

    Methods for treatment of angiogenesis
    9.
    发明申请
    Methods for treatment of angiogenesis 审中-公开
    治疗血管发生的方法

    公开(公告)号：US20090202439A1

    公开(公告)日：2009-08-13

    申请号：US11708281

    申请日：2007-02-19

    Applicant: Subroto Chatterjee

    Inventor： Subroto Chatterjee

    IPC: A61K39/395 ,  A61K31/16 ,  A61K31/5375 ,  A61K31/445 ,  A61K31/40 ,  A61K38/00 ,  A61K31/7105 ,  A61K49/00 ,  A61P35/00 ,  G01N33/53

    CPC classification number: C07K16/2803 ,  A61K31/16 ,  A61K38/00 ,  C07K16/40 ,  C07K2317/34

    Abstract: The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration to a subject one or more compounds that alter the activity of VEGF pathway members, including LacCer synthase (GalT-V/VI), PECAM1, VEGFR, VEGF or related pathway members to treat a subject suffering from or susceptible to a condition caused or contributed to by VEGF. The present invention also relates to methods for detecting and analyzing compounds with therapeutic capacity to treat such condition.

    Abstract translation: 本发明包括治疗和预防与乳糖神经酰胺相关的疾病，手术后疾病和细菌感染的方法。 所述方法通常提供给受试者一种或多种改变VEGF途径成员（包括LacCer合酶（GalT-V / VI），PECAM1，VEGFR，VEGF或相关途径成员的活性的化合物），以治疗患有或易感的受试者 由VEGF引起或促成的病症。 本发明还涉及用于检测和分析治疗这种病症的治疗能力的化合物的方法。

    Apolipoprotein c-1 induced apoptosis
    10.
    发明申请
    Apolipoprotein c-1 induced apoptosis 有权
    载脂蛋白c-1诱导凋亡

    公开(公告)号：US20070178438A1

    公开(公告)日：2007-08-02

    申请号：US10557283

    申请日：2004-05-24

    Applicant: Subroto Chatterjee ,  Peter Kwiterowich

    Inventor： Subroto Chatterjee ,  Peter Kwiterowich

    IPC: C12Q1/00 ,  C12Q1/68 ,  G01N33/567

    CPC classification number: G01N33/92 ,  G01N33/6893 ,  G01N2500/00 ,  G01N2500/04 ,  G01N2800/323 ,  G01N2800/324

    Abstract: The present invention provides methods and compositions for identifying compounds which inhibit ApoCI and which are useful in the treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for treating subjects suffering from or at risk of developing atherosclerosis, plaque rupture, apoptosis, or myocardial infarction. The invention further provides methods for diagnosing subjects at suffering from or at risk of developing treatment or prevention of atherosclerosis, plaque rupture, apoptosis, or myocardial infarction.

    Abstract translation: 本发明提供用于鉴定抑制ApoCI并可用于治疗或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的化合物的方法和组合物。 本发明还提供了治疗患有或具有发展动脉粥样硬化，斑块破裂，凋亡或心肌梗塞的风险的受试者的方法。 本发明还提供了用于诊断患有或处于或预防动脉粥样硬化，斑块破裂，凋亡或心肌梗死的受试者的方法。

Patent Agency Ranking